Pavlo Gonchar / SOPA Pictures / LightRocket by way of Getty Pictures
Key Takeaways
-
Edwards Lifesciences reduce sales-growth estimates for its greatest income, a coronary heart valve substitute therapy.
-
The center illness and demanding care monitoring firm additionally missed expectations with its second-quarter earnings.
-
Edwards Lifesciences inventory misplaced virtually a 3rd of its worth on Thursday, the worst performer within the S&P 500.
Edwards Lifesciences (EW) shares swooned Thursday, dropping after the corporate damped expectations for coronary heart valve substitute gross sales progress on Wednesday.
The corporate mentioned it expects full-year gross sales progress of 5% to 7% for its transcatheter aortic valve substitute (TAVR) therapy, down from the 8% to 10% forecast earlier. TAVR includes changing a diseased coronary heart valve utilizing a catheter relatively than by means of open-heart surgical procedure.
Full-year gross sales of transcatheter mitral and tricuspid therapies (TMTT) are anticipated to come back in on the upper finish of Edwards’ beforehand issued vary of $320 million to $340 million. The corporate reiterated its surgical gross sales progress projection of 6% to eight%.
Shares of Edwards plunged 31% to complete at $59.76 Thursday, leaving them down about 22% this yr. The inventory was the day’s worst performer within the S&P 500.
Within the second quarter, Edwards posted earnings per share (EPS) of 61 cents, falling wanting the 74 cents anticipated by analysts, in response to Seen Alpha. Income was $1.39 billion, beneath expectations. TAVR income rose 5% year-over-year to $1 billion.
Learn the unique article on Investopedia.